市場調査レポート
商品コード
1391115

コンパニオン診断の世界市場レポート 2024年

Companion Diagnostics Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
コンパニオン診断の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

コンパニオン診断市場の成長は、慢性疾患の有病率の上昇によってさらに促進されます。コンパニオン診断は、慢性疾患や非感染性疾患(NCD)において、治療計画の調整、疾患進行のモニタリング、薬剤耐性の予測などに使用されるようになってきています。世界保健機関(WHO)の報告によると、世界全体の死亡者数の74%(4,100万人相当)が毎年NCDsによって引き起こされています。特に、心血管疾患、がん、慢性呼吸器疾患、糖尿病などの疾病がこの負担に大きく寄与しています。慢性疾患の罹患率の増加は、患者の予後を改善し、市場全体の成長に貢献する上で、コンパニオン診断が不可欠な役割を担っていることを裏付けています。

2023年のコンパニオン診断市場で最大の地域は北米でした。コンパニオン診断市場レポートがカバーする地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 コンパニオン診断市場の特徴

第3章 コンパニオン診断市場の動向と戦略

第4章 コンパニオン診断市場-マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界のコンパニオン診断市場規模と成長

  • 世界のコンパニオン診断市場の促進要因と抑制要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界のコンパニオン診断市場規模実績と成長、2018~2023年
  • 世界のコンパニオン診断市場規模と成長予測、2023~2028年、2033年

第6章 コンパニオン診断市場セグメンテーション

  • 世界のコンパニオン診断市場、製品およびサービス別セグメンテーション、実績および予測、2018~2023年、2023~2028年、2033年
  • アッセイ、キット、試薬
  • ソフトウェアとサービス
  • 世界のコンパニオン診断市場、技術別セグメンテーション、実績および予測、2018~2023年、2023~2028年、2033年
  • ポリメラーゼ連鎖反応
  • 次世代シーケンス
  • in situハイブリダイゼーション
  • 免疫組織化学
  • 世界のコンパニオン診断市場、適応症別セグメンテーション、実績および予測、2018~2023年、2023~2028年、2033年
  • 肺がん
  • 乳がん
  • 結腸直腸がん
  • 白血病
  • 黒色腫
  • 世界のコンパニオン診断市場、エンドユーザー別セグメンテーション、実績および予測、2018~2023年、2023~2028年、2033年
  • 製薬会社およびバイオ医薬品会社
  • リファレンスラボ
  • 受託研究機関

第7章 コンパニオン診断市場の地域および国分析

  • 世界のコンパニオン診断市場、地域別、実績および予測、2018~2023年、2023~2028年、2033年
  • 世界のコンパニオン診断市場、国別、実績および予測、2018~2023年、2023~2028年、2033年

第8章 アジア太平洋のコンパニオン診断市場

第9章 中国のコンパニオン診断市場

第10章 インドのコンパニオン診断市場

第11章 日本のコンパニオン診断市場

第12章 オーストラリアのコンパニオン診断市場

第13章 インドネシアのコンパニオン診断市場

第14章 韓国のコンパニオン診断市場

第15章 西欧のコンパニオン診断市場

第16章 英国のコンパニオン診断市場

第17章 ドイツのコンパニオン診断市場

第18章 フランスのコンパニオン診断市場

第19章 イタリアのコンパニオン診断市場

第20章 スペインのコンパニオン診断市場

第21章 東欧のコンパニオン診断市場

第22章 ロシアのコンパニオン診断市場

第23章 北米のコンパニオン診断市場

第24章 米国のコンパニオン診断市場

第25章 カナダのコンパニオン診断市場

第26章 南米のコンパニオン診断市場

第27章 ブラジルのコンパニオン診断市場

第28章 中東のコンパニオン診断市場

第29章 アフリカのコンパニオン診断市場

第30章 コンパニオン診断市場の競合情勢と企業プロファイル

  • コンパニオン診断市場の競合情勢
  • コンパニオン診断市場の企業プロファイル
    • F Hoffmann-La Roche Ltd.
    • Agilent Technologies Inc.
    • Qiagen NV
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories Inc.

第31章 世界のコンパニオン診断市場の競合ベンチマーキング

第32章 世界のコンパニオン診断市場の競合ダッシュボード

第33章 コンパニオン診断市場における主要な合併と買収

第34章 コンパニオン診断市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r9475

“Companion Diagnostics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on companion diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for companion diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The companion diagnostics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Product And Service: Assays, Kits And Reagents; Software And Services
  • 2) By Technology: Polymerase Chain Reaction; Next-Generation Sequencing; In Situ Hybridization; Immunohistochemistry
  • 3) By Indication: Lung Cancer; Breast Cancer; Colorectal Cancer; Leukemia; Melanoma
  • 4) By End-User: Pharmaceutical And Biopharmaceutical Companies; Reference Laboratories; Contract Research Organizations
  • Companies Mentioned: F Hoffmann-La Roche Ltd.; Agilent Technologies Inc.; Qiagen NV; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Companion diagnostics refer to in vitro diagnostic medical tests employed to assess the safety and effectiveness of a corresponding drug or biological product. These tests play a crucial role in helping healthcare professionals match patients with specific drugs or therapies.

The primary products and services in the companion diagnostics market include assays, kits, reagents, software, and related services. Assays, kits, and reagents find applications in various life science, environmental, and research laboratories. Assays are procedures used to examine substances for composition or quality, kits are collections of equipment and materials for specific purposes, and reagents are chemicals used in laboratory testing. Technologies such as polymerase chain reaction, next-generation sequencing, in situ hybridization, and immunohistochemistry are employed in companion diagnostics. These diagnostic tools are instrumental in identifying various cancer diseases like lung, breast, colorectal, leukemia, and melanoma. The primary users of companion diagnostics include pharmaceutical and biopharmaceutical companies, reference laboratories, and contract research organizations.

The companion diagnostics market research report is one of a series of new reports from The Business Research Company that provides companion diagnostics market statistics, including companion diagnostics industry global market size, regional shares, competitors with a companion diagnostics market share, detailed companion diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the companion diagnostics industry. This companion diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The companion diagnostics market size has grown exponentially in recent years. It will grow from $6.26 billion in 2023 to $7.52 billion in 2024 at a compound annual growth rate (CAGR) of 20.1%. The growth in the historical period can be attributed to the increased adoption of personalized medicine, the expansion of oncology and cancer therapies, heightened collaboration in pharmaceutical research and development, the implementation of precision medicine initiatives, and advancements in biomarker discovery.

The companion diagnostics market size is expected to see exponential growth in the next few years. It will grow to $15.8 billion in 2028 at a compound annual growth rate (CAGR) of 20.4%. The growth in the forecast period can be attributed to the development of targeted therapies, advancements in infectious disease diagnostics, an increase in rare disease diagnostics, rising trends in biomarker-based drug development, the expansion of point-of-care testing, and the application of liquid biopsy. Major trends in the forecast period include advances in immunotherapy and immunology, the integration of AI and machine learning in diagnostics, product innovations, the adoption of Industry 4.0, and strategic collaborations.

The companion diagnostics market is anticipated to experience growth due to the increasing number of targeted therapies. Targeted therapy, which focuses on specific characteristics of cancer cells to hinder their growth and spread, is gaining prominence in cancer treatment. Companion diagnostics, through biological marker-based testing, play a crucial role in personalized cancer care by identifying eligibility for genome-targeted therapy. As per the European Society for Medical Oncology's April 2021 article, the estimated eligibility for genome-targeted therapy increased from 8.82% in previous years to 13.60% in 2020, reflecting the growing adoption of targeted therapies and driving the companion diagnostics market.

The growth of the companion diagnostics market is further propelled by the rising prevalence of chronic diseases. Companion diagnostics are increasingly used in chronic diseases or non-communicable diseases (NCDs) to tailor treatment plans, monitor disease progression, and predict drug resistance. The World Health Organization reported that 74% of global deaths, equivalent to 41 million, are caused by NCDs annually. Notably, diseases such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes contribute significantly to this burden. The rising incidence of chronic diseases underscores the essential role of companion diagnostics in enhancing patient outcomes and contributing to the overall growth of the market.

A key trend in the companion diagnostics market is technological advancement, particularly the integration of artificial intelligence (AI). AI is being leveraged to develop more efficient drugs and advance companion diagnostics. The extensive genetic profiling data sets, continuously generated, enable the application of AI to identify insights into disease causes. For example, Toronto-based start-up Deep Genomics is utilizing AI to expedite the discovery of better medications for genetic illnesses. Through deep learning, scientists can explore the human genome, analyze billions of chemical compounds, and identify promising formulations for clinical trials. This application of AI in companion diagnostics aligns with the broader trend of technological innovation, driving advancements in the field.

Prominent companies in the companion diagnostics market are pioneering innovative treatment solutions, exemplified by products like therascreen KRAS PCR Mutation Analysis. This diagnostic test is designed for identifying non-small cell lung cancer (NSCLC) patients and is specifically tailored for Amgen's lung cancer therapy, LUMAKRAS (sotorasib). The test, performed on tumor tissue samples, delivers results promptly, typically within a few days. Laboratory Corporation of America Holdings, a leading US-based healthcare company, launched this companion diagnostic in July 2021. It plays a crucial role in identifying patients with NSCLC whose tumors harbor the specific genetic mutation KRAS G12C. Beyond facilitating targeted therapies, the test prevents patients from undergoing ineffective treatments with potential serious side effects.

In a strategic move, Agilent Technologies Inc., a major player in analytical laboratory solutions, acquired Resolution Bioscience for $695 million in April 2021. This acquisition fortified Agilent's position in next-generation sequencing (NGS)-based cancer diagnostics. Resolution Bioscience, a US-based healthcare research company, specializes in NGS technology, molecular biology, and cancer diagnostics. The acquisition empowered Agilent to meet the escalating demands of the precision medicine sector, reflecting the industry's commitment to advancing technologies and expanding capabilities in the companion diagnostics market.

Major companies operating in the companion diagnostics market include F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Abnova Corp., Amoy Diagnostics Co. Ltd., ARUP Laboratories, Bayer AG, Biomerieux SA, Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Biogenex Laboratories Inc., Caris Life Sciences, Cepheid Inc., Diaceutics PLC, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sividon Diagnostics GmbH, Sysmex Corporation, Ventana Medical Systems, Vermillion Inc.

North America was the largest region in the companion diagnostics market in 2023. The regions covered in the companion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the companion diagnostics market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The companion diagnostics market includes revenues earned by theranostics and monitoring tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Companion Diagnostics Market Characteristics

3. Companion Diagnostics Market Trends And Strategies

4. Companion Diagnostics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Companion Diagnostics Market Size and Growth

  • 5.1. Global Companion Diagnostics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Companion Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Companion Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Companion Diagnostics Market Segmentation

  • 6.1. Global Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Assays, Kits And Reagents
  • Software And Services
  • 6.2. Global Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Polymerase Chain Reaction
  • Next-Generation Sequencing
  • In Situ Hybridization
  • Immunohistochemistry
  • 6.3. Global Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Melanoma
  • 6.4. Global Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pharmaceutical And Biopharmaceutical Companies
  • Reference Laboratories
  • Contract Research Organizations

7. Companion Diagnostics Market Regional And Country Analysis

  • 7.1. Global Companion Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Companion Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Companion Diagnostics Market

  • 8.1. Asia-Pacific Companion Diagnostics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Companion Diagnostics Market

  • 9.1. China Companion Diagnostics Market Overview
  • 9.2. China Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Companion Diagnostics Market

  • 10.1. India Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Companion Diagnostics Market

  • 11.1. Japan Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.2. Japan Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Companion Diagnostics Market

  • 12.1. Australia Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Companion Diagnostics Market

  • 13.1. Indonesia Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Companion Diagnostics Market

  • 14.1. South Korea Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.2. South Korea Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Companion Diagnostics Market

  • 15.1. Western Europe Companion Diagnostics Market Overview
  • 15.2. Western Europe Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Companion Diagnostics Market

  • 16.1. UK Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Companion Diagnostics Market

  • 17.1. Germany Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Companion Diagnostics Market

  • 18.5. France Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.6. France Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.7. France Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Companion Diagnostics Market

  • 19.9. Italy Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Companion Diagnostics Market

  • 20.13. Spain Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Companion Diagnostics Market

  • 21.1. Eastern Europe Companion Diagnostics Market Overview
  • 21.2. Eastern Europe Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Companion Diagnostics Market

  • 22.1. Russia Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Companion Diagnostics Market

  • 23.1. North America Companion Diagnostics Market Overview
  • 23.2. North America Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Companion Diagnostics Market

  • 24.1. USA Companion Diagnostics Market Overview
  • 24.2. USA Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Companion Diagnostics Market

  • 25.1. Canada Companion Diagnostics Market Overview
  • 25.2. Canada Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Companion Diagnostics Market

  • 26.1. South America Companion Diagnostics Market Overview
  • 26.2. South America Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Companion Diagnostics Market

  • 27.1. Brazil Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Companion Diagnostics Market

  • 28.1. Middle East Companion Diagnostics Market Overview
  • 28.2. Middle East Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Companion Diagnostics Market

  • 29.1. Africa Companion Diagnostics Market Overview
  • 29.2. Africa Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Companion Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Companion Diagnostics Market Competitive Landscape
  • 30.2. Companion Diagnostics Market Company Profiles
    • 30.2.1. F Hoffmann-La Roche Ltd.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Agilent Technologies Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Qiagen NV
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Thermo Fisher Scientific Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Abbott Laboratories Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Companion Diagnostics Market Competitive Benchmarking

32. Global Companion Diagnostics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Companion Diagnostics Market

34. Companion Diagnostics Market Future Outlook and Potential Analysis

  • 34.1 Companion Diagnostics Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Companion Diagnostics Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Companion Diagnostics Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer